MREO
Income statement / Annual
Last year (2024), Mereo BioPharma Group plc's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Mereo BioPharma Group plc's net income was -$43.25 M.
See Mereo BioPharma Group plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$10.00 M |
$1.51 M |
$36.46 M |
$393,000.00 |
-$122,000.00 |
$0.00 |
-$3.29 M |
$0.00 |
| Cost of Revenue |
$0.00
|
$2.57 M
|
$936,000.00
|
$17.91 M
|
$16.35 M
|
$23.61 M
|
$22.70 M
|
$34.61 M
|
$24.56 M
|
| Gross Profit |
$0.00
|
$7.43 M
|
$571,000.00
|
$18.56 M
|
-$15.95 M
|
-$23.73 M
|
-$22.70 M
|
-$37.89 M
|
-$24.56 M
|
| Gross Profit Ratio |
0
|
0.74
|
0.38
|
0.51
|
-40.6
|
194.51
|
0
|
11.53
|
0
|
| Research and Development Expenses |
$20.93 M
|
$17.42 M
|
$24.96 M
|
$23.56 M
|
-$16.35 M
|
-$23.61 M
|
$22.70 M
|
$34.61 M
|
$24.56 M
|
| General & Administrative Expenses |
$26.43 M
|
$18.42 M
|
$19.54 M
|
$15.93 M
|
$21.22 M
|
$15.91 M
|
$12.50 M
|
$10.70 M
|
$11.62 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$26.43 M
|
$18.42 M
|
$19.54 M
|
$15.93 M
|
$21.22 M
|
$15.91 M
|
$12.50 M
|
$10.70 M
|
$11.62 M
|
| Other Expenses |
$0.00
|
$0.00
|
$811,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$293,328.00
|
$0.00
|
| Operating Expenses |
$47.36 M
|
$35.84 M
|
$44.51 M
|
$39.49 M
|
$21.22 M
|
$15.91 M
|
$12.50 M
|
$10.70 M
|
$11.62 M
|
| Cost And Expenses |
$0.00
|
$38.42 M
|
$43.57 M
|
$57.40 M
|
$37.57 M
|
$39.52 M
|
$35.21 M
|
$45.30 M
|
$36.18 M
|
| Interest Income |
$3.04 M
|
$2.13 M
|
$696,000.00
|
$1,000.00
|
$44,000.00
|
$377,000.00
|
$306,831.00
|
$826,855.00
|
$195,141.00
|
| Interest Expense |
-$1.37 M
|
$2.88 M
|
$3.36 M
|
$4.00 M
|
$6.38 M
|
$3.50 M
|
$2.36 M
|
$1.09 M
|
$179,765.00
|
| Depreciation & Amortization |
-$2.74 M
|
$1.06 M
|
$1.51 M
|
$866,466.00
|
$44,000.00
|
$1.95 M
|
$37,796.00
|
$36,076.00
|
$32,940.00
|
| EBITDA |
-$47.36 M |
-$26.06 M |
-$42.06 M |
-$5.00 M |
-$37.53 M |
-$37.56 M |
-$34.86 M |
-$44.44 M |
-$38.41 M |
| EBITDA Ratio |
0
|
-2.61
|
-27.91
|
-0.14
|
-95.48
|
307.89
|
0
|
13.53
|
0
|
| Operating Income Ratio |
0
|
-2.84
|
-28.91
|
-0.57
|
-95.6
|
323.91
|
0
|
13.79
|
0
|
| Total Other Income/Expenses Net |
$4.11 M
|
-$1.58 M
|
$7.48 M
|
$40.16 M
|
-$129.27 M
|
-$1.60 M
|
-$2.10 M
|
-$1.65 M
|
$2.46 M
|
| Income Before Tax |
-$43.25 M
|
-$30.00 M
|
-$36.09 M
|
$14.24 M
|
-$166.45 M
|
-$41.12 M
|
-$37.31 M
|
-$46.95 M
|
-$33.72 M
|
| Income Before Tax Ratio |
0
|
-3
|
-23.95
|
0.39
|
-423.54
|
337.03
|
0
|
14.29
|
0
|
| Income Tax Expense |
$0.00
|
-$532,000.00
|
-$1.90 M
|
$1.52 M
|
-$2.82 M
|
-$6.27 M
|
-$5.28 M
|
-$8.15 M
|
-$5.33 M
|
| Net Income |
-$43.25 M
|
-$29.47 M
|
-$34.20 M
|
$12.73 M
|
-$163.63 M
|
-$34.84 M
|
-$32.03 M
|
-$38.80 M
|
-$28.39 M
|
| Net Income Ratio |
0
|
-2.95
|
-22.69
|
0.35
|
-416.36
|
285.61
|
0
|
11.81
|
0
|
| EPS |
-0.2925 |
-1100.22 |
-1750.35 |
749.6499 |
-16503.3 |
-12902.58 |
-14352.87 |
-19003.8 |
-19553.91 |
| EPS Diluted |
-0.2925 |
-1100.22 |
-1750.35 |
749.6499 |
-16503.3 |
-12902.58 |
-14352.87 |
-19003.8 |
-19553.91 |
| Weighted Average Shares Out |
$147.92 M
|
$131.89 M
|
$120.64 M
|
$116.73 M
|
$67.79 M
|
$17.87 M
|
$14.23 M
|
$13.80 M
|
$8.96 M
|
| Weighted Average Shares Out Diluted |
$147.92 M
|
$131.89 M
|
$120.64 M
|
$116.73 M
|
$67.79 M
|
$17.88 M
|
$14.23 M
|
$13.80 M
|
$8.96 M
|
| Link |
|
|
|
|
|
|
|
|
|
